Abcellera Biologics Inc. · NASDAQ:ABCL

Abcellera Biologics — Q3 2024 Earnings Presentation

10 slides from Abcellera Biologics's earnings presentation, Nov 4, 2024

Slide 2: Disclaimer
DISCLAIMER This presentation contains forward-looking statements, including statements made These statements involve risks, uncertainties and other factors that may cause pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act actual results, levels of activity, perfor
Slide 3: We are executing on our key priorities
Q3 2024 UPDATE We are executing on our key priorities. Internal Programs & Pipeline Engine & Capabilities Strategic Partnerships Clinical Trial Application (CTA) for Moved into new headquarters, Building on co-development ABCL635 anticipated in Q2 2025 which was initiated in 2020 collaborations Clin
Slide 5: Continued progress on key business metrics
~$875M in available liquidity to execute on our strategy Continued ~$670M in total cash, cash equivalents, & progress on key marketable securities Q3 2024 Business Update business metrics 95 cumulative partner-initiated program starts with downstreams and a strong 14 molecules in cash position. the
Slide 6: Continuing portfolio growth
Continuing portfolio growth. Cumulative # of Cumulative # of Notable Updates on PARTNER-INITIATED PROGRAM STARTS MOLECULES IN THE CLINIC WITH DOWNSTREAMS Q3 2024 Business Update Molecule This Quarter’s Update ABD-147 New: received orphan-disease designation COPYRIGHT © ABCELLERA Note: Showing year-e
Slide 7: Operating expenses reflect ongoing investments, offset by $7M revenue
Operating expenses reﬂect ongoing investments, predominantly in R&D; partly offset by $7M in revenue. Revenue USD Operating Expenses USD Q3 2024 Business Update COPYRIGHT © ABCELLERA 7
Slide 9: Approximately $670M in total cash, equivalents, and marketable securities
Approximately $670M in total cash, equivalents, and marketable securities. Cash Flows USD Q3 2024 Business Update COPYRIGHT © ABCELLERA * Restricted cash (including restricted cash in other assets) 9

AbCellera Biologics — Q3 2024 Earnings Presentation on 6ix

Abcellera Biologics — Q3 2024 Earnings Presentation

Slide 1: Q3 2024 Business Update

Slide 2: Disclaimer

Slide 3: We are executing on our key priorities

Slide 4: Financials Update

Slide 5: Continued progress on key business metrics

Slide 6: Continuing portfolio growth

Slide 7: Operating expenses reflect ongoing investments, offset by $7M revenue

Slide 8: Net loss of $51M; ($0.17) per share

Slide 9: Approximately $670M in total cash, equivalents, and marketable securities

Slide 10: Thank You